May 2006
Volume 47, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2006
CD4+/NK1.1+NKT Cells Play Important Role in SEB Induced Tolerence in Treating Rat High–Risk Corneal Transplantation
Author Affiliations & Notes
  • Y. Jie
    Corneal Immunology, Beijing institute of ophthalmology, Beijing Tongren eye centre,Tongren hospital, Beijing, China
  • Z. Pan
    Tongren eye bank, Beijing Tongren eye center, Beijing, China
  • L. Xu
    Glaucoma, Beijing Institute of Ophthalmology,Beijing Tongren eye center, Beijing, China
  • Y. Chen
    Department of Immunology, General Hospital of PLA, Beijing, China
  • W. Zhang
    Corneal Immunology, Beijing institute of ophthalmology, Beijing Tongren eye centre,Tongren hospital, Beijing, China
  • Y. Wu
    Corneal Immunology, Beijing institute of ophthalmology, Beijing Tongren eye centre,Tongren hospital, Beijing, China
  • H. Peng
    Immunology, Academy of Military Medical Sciences, Beijing, China
  • Footnotes
    Commercial Relationships  Y. Jie, None; Z. Pan, None; L. Xu, None; Y. Chen, None; W. Zhang, None; Y. Wu, None; H. Peng, None.
  • Footnotes
    Support  National Natural Science Foundation of China under project NO: 30271385
Investigative Ophthalmology & Visual Science May 2006, Vol.47, 1294. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Y. Jie, Z. Pan, L. Xu, Y. Chen, W. Zhang, Y. Wu, H. Peng; CD4+/NK1.1+NKT Cells Play Important Role in SEB Induced Tolerence in Treating Rat High–Risk Corneal Transplantation . Invest. Ophthalmol. Vis. Sci. 2006;47(13):1294.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : The role of CD4+/NK1.1+NKT cells in superantigen Staphylococcal enterotoxin B induced immune tolerance in rat high–risk keratoplasty was studied.

Methods: : F344 donor corneas were transplanted into Lewis recipients. Corneal neovascularization was induced by three interrupted sutures in the host corneas for 1 week. All the recipient rats were divided in a masked fashion into SEB–treated subgroup, SEB combined with glucocorticoid–treated subgroup and the control group. The SEB subgroup was intraperitoneally injected with 0.2ml SEB of 75µg/kg before transplantation at 4 days interval for together 3 times. The drug combination subgroup received SEB as above, meanwhile 0.1 ml glucocorticoid at concentration of 5mg/ml was injected subconjunctivally after surgery for 3 days. The control group received saline buffer in the same way as SEB. All transplants were evaluated for 4 weeks after surgery for signs of rejection. Ten days after transplantation, three recipients in each group were sacrificed and the blood, spleens, and mandibular lymph nodes were taken for lymphocyte proliferation assay and flow cytometery analysis. IL–2 and IL–10 in the aqueous humor and the serum were assayed by ELIAS.

Results: : The survival time of the allografts in the control group was 7.30±0.67d, while 12.50±1.41d in the SEB–treated subgroup and 10.38±3.07d in the drug combination subgroup. The lymphocyte proliferation ability of the SEB subgroup and the drug combination subgroup was much weaker than the control group, while the former was the weakest. The flow cytometery analysis showed the percentage of CD4+/NK1.1+NKT cells in the peripheral lymphatic organs was higher in the SEB subgroup and the drug combination subgroup, while the former was the highest. The level of IL–2 in the aqueous humor and the serum in both the SEB group and the drug combination group was lower but the level of IL–10 was higher than the control group.

Conclusions: : SEB could induce immune tolerence in high–risk corneal transplantation and prolong the survival time of the allografts. The induction of tolerance may be related to the up–regulation of CD4+/ NK1.1+ NK T cells.

Keywords: cornea: basic science • immunomodulation/immunoregulation • cytology 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×